[go: up one dir, main page]

USRE29474E - Method for the determination of proteins and polypeptides - Google Patents

Method for the determination of proteins and polypeptides Download PDF

Info

Publication number
USRE29474E
USRE29474E US05/598,141 US59814175A USRE29474E US RE29474 E USRE29474 E US RE29474E US 59814175 A US59814175 A US 59814175A US RE29474 E USRE29474 E US RE29474E
Authority
US
United States
Prior art keywords
iaddend
iadd
antibodies
group
labeled
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US05/598,141
Inventor
Rolf E. A. V. Axen
Jerker O. Porath
Leif Edvin Wide
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Pharmacia AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE7541/66A external-priority patent/SE343949B/xx
Application filed by Pharmacia AB filed Critical Pharmacia AB
Priority to US05/598,141 priority Critical patent/USRE29474E/en
Application granted granted Critical
Publication of USRE29474E publication Critical patent/USRE29474E/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors

Definitions

  • the present invention relates to a method for the determination of proteins and polypeptides, for instance protein and polypeptide, hormones, in aqueous samples, e.g. from body fluids such as blood serum or urine, but also from other sources such as different types of gland extracts.
  • aqueous samples e.g. from body fluids such as blood serum or urine, but also from other sources such as different types of gland extracts.
  • An essential factor of the method is that the substance to be determined is capable of acting as an antigen, i.e. is capable of causing the formation of antibodies against itself in animals.
  • the invention is characterized in that particles of water insoluble polymers to which have been bound antibodies, by means of covalent bonds, against the protein or polypeptide to be determined, are contacted with the sample and with a certain quantity of the protein or polypeptide labeled with a radioactive isotope, whereupon the particles, subsequent to the reaction between the protein or the polypeptide and the antibodies attached to the particles having taken place, are separated from the sample liquid and the radioactivity of the particle material and/or in the liquid is determined.
  • the method can be used for qualitative and quantitative determination.
  • the invention is based partly upon the knowledge that under certain circumstances proteins and polypeptides are generally able to act as antigens, i.e. able to cause the formation of antibodies, and partly on the fact that radioimmunological methods are very sensitive and well suited for determining different proteins and polypeptides, present in a very low concentration in body fluids.
  • Radioimmunological methods are in general based on the ability of an antibody to bind its protein antigen irrespective of whether the latter is labeled with a radioactive isotope, or not.
  • the binding of labeled and unlabeled protein antigens takes place in proportion to the concentration of labeled and unlabeled, respectively, proteins.
  • the radioactivity of the labeled protein which is bound to the antibodies, and/or of the free, labeled protein in the sample liquid is measured.
  • the amount of unlabeled competing protein can be determined from the obtained values by calculation or by direct comparison with a standard curve.
  • radioimmunological methods can be applied to proteins and polypeptides which are antigenic, capable of being purified and labeled with a radioactive isotope.
  • the antibody bound protein has to be separated from the unbound protein.
  • This separation process has previously been effected by a large number of different methods, such as paper chromotography, electrophoresis, precipitation with a salt or ethyl alcohol, precipitation of antibodies by antibodies against the latter or gel filtration.
  • These methods are complicated, time consuming, unpractical and unreliable for use in routine tests, e.g. in an ordinary hospital laboratory.
  • the great advantage of the present method is that the antibodies are firmly attached to an insoluble carrier and that the labeled protein, which reacts with and is bound to the antibodies in the determination, can thus be easily separated from the unbound labeled protein, e.g. by simple centrifugation, or filtration, the separation being insensitive to variations in the salt and protein concentrations of the liquid within physiological limits.
  • the test is easy to perform as known amounts of particles together with antibodies attached thereto, can be predispensed in test tubes, for instance, and stored without loosing the binding ability.
  • the whole procedure, including the separation of the free labeled proteins and antibody bound labeled proteins, can be made in one and the same test tube without any further addition of precipitants or the like.
  • the method requires access to the protein or the polypeptide to be determined for producing antibodies and for preparing radioactive labeled proteins or polypeptides, and suitably also for obtaining standard solutions, for instance, for obtaining standard curves.
  • proteins and polypeptides against which antibodies can be obtained are plasma proteins, enzymes and many hormones.
  • hormones are insulin, gonadotropins, growth hormone. ACTH, thyrotropin and parathormone.
  • the antibodies against the protein or the polypeptide can be prepared by any method known per se, by immunising animals used for experiments, by, for instance, repeated subcutaneous injections of small amounts of the antigenic protein or polypeptide possible combined with a so-called adjuvant such as Freund's mineral oil emulsion, into the animal.
  • the antibodies produced in the animals can be recovered from the blood serum of the same.
  • the protein fraction, which contains the antiserum can be recovered by conventional methods, e.g. by precipitating the serum with suitable amounts of a saturated aqueous solution of ammonium sulphate.
  • Labeling of the protein or polypeptide with a radioactive isotope can be effected in a conventional manner, a suitable isotope for the purpose being selected, e.g. I 125 , I 131 , C 14 or H 3 .
  • a particularly suitable isotope is a radioactive isotope of iodine such as I 125 , as labeling with this isotope is simple and as, for instance, many hospital laboratories now have the equipment necessary to measure this isotope.
  • Particles of water insoluble polymers are used as carriers for the antibodies.
  • the polymer is selected so that it contains, or can be provided with, suitable reactive groups such as amino groups, hydroxyl groups and carboxylic groups, to readily make possible the binding of the antibodies to the polymer by bridges with covalent linkages.
  • polymer particles consisting of a three dimensional network, held together by covalent linkages. Such particles even though they are swellable in water, are completely insoluble therein and are thus unable to release any of the polymer material or of the substance bound thereto by covalent linkages, e.g. during washing procedures.
  • polymer particles are grains of copolymers obtained by cross linking substances containing a plurality of hydroxyl groups, such as carbohydrates and sugar alcohols, such as dextran, starch, dextrins and other polysaccharides, and polyvinyl alcohol with a bi-functional substance, e.g.
  • bi-functional substances of the type X--R--Z wherein, for instance, X and Z are each halogen or an epoxy group and R is the residue of the bi-functional substance, e.g. an aliphatic radical containing from 3 to 10 inclusive carbon atoms.
  • Sephadex which is dextran cross-linked with glycerine ether-bridges, obtained by treating dextran with epichlorohydrin, for instance, can be used for the purpose.
  • Sephadex and products obtained in a similar manner are gel grains capable of swelling in water, but insoluble therein. They contain hydroxyl groups and can thus easily be substituted with other groups, e.g. groups containing amino groups or carboxyl groups, and are thus well suited for forming bridges by covalent bonds to the antibodies.
  • small particles are chosen so that a wide contact area is obtained.
  • the antibodies are bound to the said carrier particles with covalent bonds under mild conditions so that the immuno-chemical reactivity of the antibodies does not substantially decrease. Because of the covalent binding the antibodies cannot loosen and become washed away from the particles.
  • Reactive groups such as amino groups, hydroxyl groups, and carboxyl groups, are used for chemically binding the antibody protein with the polymer particle, a bridge having covalent bonds being established between the antibody protein and the polymer particle, e.g. of the type:
  • Antibody--N N-- Polymer particle.
  • the radioactivity determinations can be effected by common methods, e.g. by means of scintillation detectors.
  • the quantity of particles with antibodies is selected, among other things, with thought to the sensitivity level required in the test.
  • the amount of labeled protein or polypeptide, e.g. I 125 hormone, added in the reaction is chosen so that, for instance, approximately 40-60% of the labeled hormone can be bound to the antibodies when no competing unlabeled hormone is present.
  • the incubation is preferably made at temperatures between +4 and 37° C. and usually at room temperature. It is not necessary for the reaction between the antigen and the antibodies to go to completion. The reaction is interrupted after, for instance, 24 hours, but may also be stopped earlier, for instance, after 2-4 hours. It is important that the reaction time and temperature are the same for the sample solutions and standard solutions.
  • FIG. 1 is a curve showing counts per minute plotted as a function of the concentration of gonadotropin (in international units) in a series of standard solutions, said count being obtained according to Example 1 and said curve being possible to use for the determination of gonadotropin in unknown samples as indicated by the dashed lines;
  • FIG. 2 is a curve showing counts per 10 minutes plotted as a function of the concentration of growth hormone (in nanograms per ml.) in a series of standard solutions, said counts being obtained according to Example 2 and said curve being illustrated as used for the determination of growth hormone in unknown samples obtained from a patient after glucose loading at 0 min; at 0 plus 17 min.; and at 0 plus 80 min., respectively, and
  • FIG. 3 is a curve showing counts per 5 minutes plotted as a function of the concentration of insulin in micro units, ⁇ u, in a series of standard solutions per ml., said counts being obtained according to Example 3 and said curve being illustrated as used for the determination of insulin in unknown samples obtained from a patient after glucose loading at 0 min.; at 0+7 min.; at 0+12 min.; at 0+17 min.; at 0+22 min.; and at 0+40 min. respectively.
  • the antibody fraction was precipitated from this antiserum by treatment with a saturated aqueous solution of ammonium sulphate, 2.5 ml. of the saturated solution being added to 5 ml. of serum.
  • the precipitate was separated by centrifugation.
  • the precipitate was dissolved in water and the precipitating process with ammonium sulphate solution was repeated twice. Subsequent to the third precipitating process the precipitate was dissolved in 0.1 ml. of an aqueous solution of sodium hydrogen carbonate after which dialysis took place against 0.1 M sodium hydrogen carbonate solution. This antibody fraction was used for the coupling.
  • the mixture was agitated and at the same time there were supplied 25 ml. of a 5 N aqueous solution of sodium hydroxide and 6 grams of sodium dithionite for reducing the nitro groups into amino groups. After approximately 30 minutes a further 5 grams of sodium dithionite were added. The reduction process was interrupted after approximately 1 hour whereupon neutralization took place with diluted hydrochloric acid, the solid substance being removed by filtering and washed with distilled water on a suction filter.
  • the Sephadex product obtained according to the above, substituted with p-isothiocyanato-phenoxy-hydroxypropyl groups was swollen in 30 ml. of a 0.1 M aqueous solution of sodium hydrogen carbonate.
  • the agitator was connected, whereupon 5 ml. of the dialysed antibody solution according to (A) was added in a drop-wise manner.
  • the mixture was agitated for 24 hours at 20° C, whereupon it was filtered.
  • the filter residue was washed with 0.5 M sodium hydrogen carbonate solution to remove the unbound substances.
  • the product can be dried carefully, e.g. by lyophilization.
  • the obtained gonadotropin labeled with I 125 was separated from low molecular weight products by gel filtration on a copolymer of dextran with epichlorohydrin (Sephadex G-50).
  • the gonadotropin labeled in this way has a specific activity of 200-300 mc. per mg. 1 ml. of the labeled protein fraction was collected in a small vessel containing 1/2 ml. of a solution of bovine plasma-albumin containing 50 mg. per ml.
  • the labeled hormone was stored in cold surroundings and diluted before being used.
  • 1 ml. of transferred supernatant can be transferred into counter tubes, whereupon the gamma radiation from the free labeled hormone can be estimated.
  • Counter tubes can, in the same way, be entered into a count-dose diagram in lin-log scale and the amount of gonadotropin in the unknown test samples can then be estimated graphically from the connecting points in the same way as above.
  • the antibody fraction was precipitated from this antiserum by treatment with an aqueous solution of saturated ammonium sulphate, 2.5 ml. of the latter being added to 5 ml. of serum.
  • the precipitate was separated by centrifugation.
  • the precipitate was dissolved in water and the precipitating process with ammonium sulphate solution was repeated twice. Subsequent to the third precipitating process the precipitate was dissolved in 0.1 ml. of an aqueous solution of sodium hydrogen carbonate after which dialysis took place against 0.1 M sodium hydrogen carbonate solution. This antibody fraction was used for the coupling.
  • the growth hormone labeled in this way has a specific activity of 200-300 mc. per mg. 1 ml. of the labeled protein fraction was collected in a small vessel containing 1/2 ml. of a solution of bovine plasma-albumin containing 50 ml. per ml.
  • the labeled hormone was stored in cold surroundings and diluted before being used.
  • 1 ml. of supernatant can be transferred into counter tubes, whereupon the gamma radiation from the free, labeled hormone can be estimated.
  • Counter tubes can, in the same way, be entered into a count-dose diagram in lin-log scale and the amount of the growth hormone in the unknown test samples can then be estimated graphically from the connecting points in the same way as above.
  • the antibody fraction was precipitated from this anti-serum by treatment with a saturated aqueous solution of ammonium sulphate solution, 2.5 ml. of the latter being added to 5 ml. of serum.
  • the precipitate was separated by centriguation.
  • the precipitate was dissolved in water and the precipitating process with ammonium sulphate solution was repeated twice. Subsequent to the third precipitating process the precipitate was dissolved in 0.1 ml. of an aqueous solution of sodium hydrogen carbonate, after which dialysis took place against 0.1 M sodium hydrogen carbonate solution. This antibody fraction was used for the coupling.
  • the obtained insulin labeled with I 125 was mixed with bovine plasma-albumin and separated from low molecular weight products and from denaturation products of insulin bound to the plasma-albumin by gel filtration on a copolymer dextran with epichlorohydrin (Sephadex G-50).
  • the insulin labeled in this way has a specific activity of 100-200 mc. per mg.
  • the second peak of the labeled protein fraction was collected in a small vessel containing 1/2 ml. of a solution of bovine plasma-albumin containing 50 mg. per ml.
  • the labeled hormone was stored in cold surroundings and diluted before being used.
  • 1 ml. of supernatant can be transferred into counter tubes, whereupon the gamma radiation from the free, labeled hormone can be estimated.
  • Counter tubes can, in the same way, be entered into a count-dose diagram in lin-log scale and the amount of insulin in the unknown test samples can then be estimated graphically from the connecting points in the same way as above.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A process comprising contacting particles of water insoluble polymers to which have been bound antibodies, by means of covalent bonds, against the protein or polypeptide to be determined, wherein a certain quantity of the protein or polypeptide is labeled with a radioactive isotope, whereupon the particles, subsequent to the reaction between the protein or the polypeptide and the antibodies attached to the particles are separated from the sample liquid and the radioactivity of the particle material and/or in the liquid is determined.

Description

The present invention relates to a method for the determination of proteins and polypeptides, for instance protein and polypeptide, hormones, in aqueous samples, e.g. from body fluids such as blood serum or urine, but also from other sources such as different types of gland extracts. An essential factor of the method is that the substance to be determined is capable of acting as an antigen, i.e. is capable of causing the formation of antibodies against itself in animals.
The invention is characterized in that particles of water insoluble polymers to which have been bound antibodies, by means of covalent bonds, against the protein or polypeptide to be determined, are contacted with the sample and with a certain quantity of the protein or polypeptide labeled with a radioactive isotope, whereupon the particles, subsequent to the reaction between the protein or the polypeptide and the antibodies attached to the particles having taken place, are separated from the sample liquid and the radioactivity of the particle material and/or in the liquid is determined.
The method can be used for qualitative and quantitative determination.
The invention is based partly upon the knowledge that under certain circumstances proteins and polypeptides are generally able to act as antigens, i.e. able to cause the formation of antibodies, and partly on the fact that radioimmunological methods are very sensitive and well suited for determining different proteins and polypeptides, present in a very low concentration in body fluids.
Radioimmunological methods are in general based on the ability of an antibody to bind its protein antigen irrespective of whether the latter is labeled with a radioactive isotope, or not. The binding of labeled and unlabeled protein antigens takes place in proportion to the concentration of labeled and unlabeled, respectively, proteins. The radioactivity of the labeled protein which is bound to the antibodies, and/or of the free, labeled protein in the sample liquid is measured. The amount of unlabeled competing protein can be determined from the obtained values by calculation or by direct comparison with a standard curve.
In principle, radioimmunological methods can be applied to proteins and polypeptides which are antigenic, capable of being purified and labeled with a radioactive isotope. The antibody bound protein has to be separated from the unbound protein. This separation process has previously been effected by a large number of different methods, such as paper chromotography, electrophoresis, precipitation with a salt or ethyl alcohol, precipitation of antibodies by antibodies against the latter or gel filtration. These methods are complicated, time consuming, unpractical and unreliable for use in routine tests, e.g. in an ordinary hospital laboratory.
The great advantage of the present method is that the antibodies are firmly attached to an insoluble carrier and that the labeled protein, which reacts with and is bound to the antibodies in the determination, can thus be easily separated from the unbound labeled protein, e.g. by simple centrifugation, or filtration, the separation being insensitive to variations in the salt and protein concentrations of the liquid within physiological limits. The test is easy to perform as known amounts of particles together with antibodies attached thereto, can be predispensed in test tubes, for instance, and stored without loosing the binding ability. The whole procedure, including the separation of the free labeled proteins and antibody bound labeled proteins, can be made in one and the same test tube without any further addition of precipitants or the like.
The method requires access to the protein or the polypeptide to be determined for producing antibodies and for preparing radioactive labeled proteins or polypeptides, and suitably also for obtaining standard solutions, for instance, for obtaining standard curves.
Examples of proteins and polypeptides against which antibodies can be obtained are plasma proteins, enzymes and many hormones. Examples of such hormones are insulin, gonadotropins, growth hormone. ACTH, thyrotropin and parathormone.
The antibodies against the protein or the polypeptide can be prepared by any method known per se, by immunising animals used for experiments, by, for instance, repeated subcutaneous injections of small amounts of the antigenic protein or polypeptide possible combined with a so-called adjuvant such as Freund's mineral oil emulsion, into the animal. The antibodies produced in the animals can be recovered from the blood serum of the same. The protein fraction, which contains the antiserum, can be recovered by conventional methods, e.g. by precipitating the serum with suitable amounts of a saturated aqueous solution of ammonium sulphate.
Labeling of the protein or polypeptide with a radioactive isotope can be effected in a conventional manner, a suitable isotope for the purpose being selected, e.g. I125, I131, C14 or H3. A particularly suitable isotope is a radioactive isotope of iodine such as I125, as labeling with this isotope is simple and as, for instance, many hospital laboratories now have the equipment necessary to measure this isotope.
Particles of water insoluble polymers are used as carriers for the antibodies. The polymer is selected so that it contains, or can be provided with, suitable reactive groups such as amino groups, hydroxyl groups and carboxylic groups, to readily make possible the binding of the antibodies to the polymer by bridges with covalent linkages.
Particularly suitable is the choice of polymer particles consisting of a three dimensional network, held together by covalent linkages. Such particles even though they are swellable in water, are completely insoluble therein and are thus unable to release any of the polymer material or of the substance bound thereto by covalent linkages, e.g. during washing procedures. Examples of such polymer particles are grains of copolymers obtained by cross linking substances containing a plurality of hydroxyl groups, such as carbohydrates and sugar alcohols, such as dextran, starch, dextrins and other polysaccharides, and polyvinyl alcohol with a bi-functional substance, e.g. bi-functional substances of the type X--R--Z, wherein, for instance, X and Z are each halogen or an epoxy group and R is the residue of the bi-functional substance, e.g. an aliphatic radical containing from 3 to 10 inclusive carbon atoms.
Grains of the commercially accessible product Sephadex which is dextran cross-linked with glycerine ether-bridges, obtained by treating dextran with epichlorohydrin, for instance, can be used for the purpose. Sephadex and products obtained in a similar manner are gel grains capable of swelling in water, but insoluble therein. They contain hydroxyl groups and can thus easily be substituted with other groups, e.g. groups containing amino groups or carboxyl groups, and are thus well suited for forming bridges by covalent bonds to the antibodies.
Suitably, small particles are chosen so that a wide contact area is obtained.
The antibodies are bound to the said carrier particles with covalent bonds under mild conditions so that the immuno-chemical reactivity of the antibodies does not substantially decrease. Because of the covalent binding the antibodies cannot loosen and become washed away from the particles. Reactive groups, such as amino groups, hydroxyl groups, and carboxyl groups, are used for chemically binding the antibody protein with the polymer particle, a bridge having covalent bonds being established between the antibody protein and the polymer particle, e.g. of the type:
Antibody--NH.CS.NL.Polymer particle
Antibody--NH.CO.NH.Polymer particle
Antibody--N=N-- Polymer particle.
Further, in the analysis a solution of the protein or polypeptide of known concentration is suitably used as a standard.
The radioactivity determinations can be effected by common methods, e.g. by means of scintillation detectors.
The quantity of particles with antibodies is selected, among other things, with thought to the sensitivity level required in the test.
The amount of labeled protein or polypeptide, e.g. I125 hormone, added in the reaction is chosen so that, for instance, approximately 40-60% of the labeled hormone can be bound to the antibodies when no competing unlabeled hormone is present. The incubation is preferably made at temperatures between +4 and 37° C. and usually at room temperature. It is not necessary for the reaction between the antigen and the antibodies to go to completion. The reaction is interrupted after, for instance, 24 hours, but may also be stopped earlier, for instance, after 2-4 hours. It is important that the reaction time and temperature are the same for the sample solutions and standard solutions.
Because the method is simple, rapid and practical, and gives accurate analysis results it is well suited for quantitative determinations, also for routine usage and permits determination of even very small amounts of sample substances.
The invention will be more closely illustrated in the following with reference to detailed examples and the annexed drawings.
In the annexed drawings,
FIG. 1 is a curve showing counts per minute plotted as a function of the concentration of gonadotropin (in international units) in a series of standard solutions, said count being obtained according to Example 1 and said curve being possible to use for the determination of gonadotropin in unknown samples as indicated by the dashed lines;
FIG. 2 is a curve showing counts per 10 minutes plotted as a function of the concentration of growth hormone (in nanograms per ml.) in a series of standard solutions, said counts being obtained according to Example 2 and said curve being illustrated as used for the determination of growth hormone in unknown samples obtained from a patient after glucose loading at 0 min; at 0 plus 17 min.; and at 0 plus 80 min., respectively, and
FIG. 3 is a curve showing counts per 5 minutes plotted as a function of the concentration of insulin in micro units, μu, in a series of standard solutions per ml., said counts being obtained according to Example 3 and said curve being illustrated as used for the determination of insulin in unknown samples obtained from a patient after glucose loading at 0 min.; at 0+7 min.; at 0+12 min.; at 0+17 min.; at 0+22 min.; and at 0+40 min. respectively.
EXAMPLE 1 Determination of Gonadotropin in Urine
(A) Preparation of antibodies: Rabbits were injected subcutaneously with 0.5 mg. of human gonadotropin in 2 ml. of Freund's adjuvant. Immunization was repeated every week for four weeks. Subsequent to the passing of a further week, blood was drawn off from the rabbits and antiserum recovered from the blood by allowing the same to coagulate, and removing the clots of blood.
The antibody fraction was precipitated from this antiserum by treatment with a saturated aqueous solution of ammonium sulphate, 2.5 ml. of the saturated solution being added to 5 ml. of serum.
The precipitate was separated by centrifugation. The precipitate was dissolved in water and the precipitating process with ammonium sulphate solution was repeated twice. Subsequent to the third precipitating process the precipitate was dissolved in 0.1 ml. of an aqueous solution of sodium hydrogen carbonate after which dialysis took place against 0.1 M sodium hydrogen carbonate solution. This antibody fraction was used for the coupling.
(B) Preparation of particles with covalently bound antibodies; Finely grained particles of the product Sephadex (G 25, superfine) were used as a starting material, the product being dextran cross-linked with glycerine ether-bridges and substituted with p-nitrophenoxy-hydroxy-propyl-ether groups to a substitution degree of 200 μmol nitro groups per gram of dry substance. (The product had been obtained by reacting Sephadex G 25, superfine, with 2,3-epoxy-1-(4-nitrophenoxy)-propane in alkaline milieu.) 10 grams of the substituted Sephadex product were introduced together with 50 ml. of water, into a two-necked flask, after which the temperature of the mixture was maintained at 35° C. The mixture was agitated and at the same time there were supplied 25 ml. of a 5 N aqueous solution of sodium hydroxide and 6 grams of sodium dithionite for reducing the nitro groups into amino groups. After approximately 30 minutes a further 5 grams of sodium dithionite were added. The reduction process was interrupted after approximately 1 hour whereupon neutralization took place with diluted hydrochloric acid, the solid substance being removed by filtering and washed with distilled water on a suction filter.
10 grams of the above obtained Sephadex product substituted with p-amino-phenoxy-hydroxy-propyl groups were introduced into a reaction flask together with 100 ml. of a 10 percent solution of thiophosgene in carbon tetrachloride. The flask was sealed with a plug and the mixture agitated for approximately 2 hours. The obtained mixture was cooled in an ice bath whereupon the flask was opened and the contents filtered. The residue of filtration was washed with a 0.1 mol aqueous solution of sodium hydrogen carbonate, distilled water and acetone. The residue was then dried in a drying oven at 60-80° C. The Sephadex product, obtained according to the above, substituted with p-isothiocyanato-phenoxy-hydroxypropyl groups was swollen in 30 ml. of a 0.1 M aqueous solution of sodium hydrogen carbonate. The agitator was connected, whereupon 5 ml. of the dialysed antibody solution according to (A) was added in a drop-wise manner. The mixture was agitated for 24 hours at 20° C, whereupon it was filtered. The filter residue was washed with 0.5 M sodium hydrogen carbonate solution to remove the unbound substances. The product can be dried carefully, e.g. by lyophilization.
(C) Preparation of labeled gonadotropin: Human gonadotropin was labeled with I125 according to the following method: 2 mc. I125 in the form of NaI was oxidized with Chloramine T in the presence of 5 μg. of gonadotropin in accordance with a method described by Hunter and Greenwood (ref. Nature/London/, volume 194/1962/, page 495). Subsequent to the labeling, sodium dithionite was added to convert the remaining amount of iodine to soluble iodide. The obtained gonadotropin labeled with I125 was separated from low molecular weight products by gel filtration on a copolymer of dextran with epichlorohydrin (Sephadex G-50). The gonadotropin labeled in this way has a specific activity of 200-300 mc. per mg. 1 ml. of the labeled protein fraction was collected in a small vessel containing 1/2 ml. of a solution of bovine plasma-albumin containing 50 mg. per ml. The labeled hormone was stored in cold surroundings and diluted before being used.
(D) Determination: The analyses are suitably effected in glass or plastic tubes 50 × 10 mm. in size.
(1) 1 ml. of a suspension of polymer particles (e.g. 1 mg./ml.) to which the antibodies have been found was introduced into each of eight tubes designated, respectively, A, B, C, D, E, F, G and H.
(2) 0.25 ml. of the urine sample to be tested was added to one of the tubes (tube A).
(3) 0.25 ml. of standard solutions containing 100, 50, 25, 10, 5, 2.5 and 0.1E per liter was added to, respectively, tubes B, C, D, E, F, G and H.
(4) Incubation took place for 20 hours at room temperature, the tubes being slowly rotated during the incubation period.
(5) 0.1 ml. of the solution containing I125 gonadotropin (approximately 1 nanogram per ml.) was added to each of the tubes A-H.
The abbreviation "IE" means "international units" (E=German Einheiten). In this connection, reference is made to World Health Organization Technical Report Series No. 293 WHO Expert Committee on Biological Standardization 17 e report Geneve 1964, page 12.
(6) Incubation as in item (4) but only for four hours.
(7) The particles were centrifuged down at 3000 revolutions per min. for 5 minutes.
(8) The particles were washed twice with a 0.9 percent aqueous solution of sodium chloride. After the last removal by suction of the supernatant the tubes were placed in counter tubes for estimating gamma radiation from the antibody bound labeled hormone.
(9) The number of "counts" for a certain time for standard tubes were entered on a counts-dose diagram on a lin-log scale, from which the amount of gonadotropin in the unknown test samples could then be calculated. (See separate FIG. 1).
Alternatively subsequent to the centrifuging in item (7) 1 ml. of transferred supernatant can be transferred into counter tubes, whereupon the gamma radiation from the free labeled hormone can be estimated. "Counts" from these standard tubes can, in the same way, be entered into a count-dose diagram in lin-log scale and the amount of gonadotropin in the unknown test samples can then be estimated graphically from the connecting points in the same way as above.
EXAMPLE 2 Determination of Growth Hormone in Blood Plasma
(A) Preparation of antibodies: Guinea pigs were injected subcutaneously with 0.5 mg. of human growth hormone in 2 ml. of Freund's adjuvant. Immunization was repeated every week for four weeks. Subsequent to the passing of a further week, blood was drawn off from the guinea pigs and antiserum recovered from the blood by allowing the same to coagulate, and removing the clots of blood.
The antibody fraction was precipitated from this antiserum by treatment with an aqueous solution of saturated ammonium sulphate, 2.5 ml. of the latter being added to 5 ml. of serum.
The precipitate was separated by centrifugation. The precipitate was dissolved in water and the precipitating process with ammonium sulphate solution was repeated twice. Subsequent to the third precipitating process the precipitate was dissolved in 0.1 ml. of an aqueous solution of sodium hydrogen carbonate after which dialysis took place against 0.1 M sodium hydrogen carbonate solution. This antibody fraction was used for the coupling.
(B) Preparation of particles with covalently bound antibodies: The preparation takes place in the same manner as under Example 1(B).
(C) Preparation of labeled growth hormone: Human growth hormone was labeled with I125 according to the following method: 2 mc. I125 in the form of NaI was oxidized with Chloramine T in the presence of 5 μg. of growth hormone in accordance with a method described by Hunter and Greenwood (ref. Nature/London/, volume 194/1962/, page 495). Subsequent to the labeling, sodium dithionite was added to convert the remaining amount of iodine to soluble iodide. The obtained growth hormone labeled with I125 was separated from low molecular weight products by gel filtration on a copolymer dextran with epichlorohydrin (Sephadex G-50). The growth hormone labeled in this way has a specific activity of 200-300 mc. per mg. 1 ml. of the labeled protein fraction was collected in a small vessel containing 1/2 ml. of a solution of bovine plasma-albumin containing 50 ml. per ml. The labeled hormone was stored in cold surroundings and diluted before being used.
(D) Determination: The analyses are suitably effected in glass or plastic tubes 50 × 10 mm.
(1) 1 ml. of a suspension of polymer particles (e.g. 1 mg./ml.) to which the antibodies have been bound was introduced into each of all tubes.
(2) 0.1 ml. of the plasma to be tested was added to one tube.
(3) 0.1 ml. of standard solution having different concentration of the hormone, e.g. 20, 10, 5, 2, 1, 0.5 and 0.2 nanogram per ml. and 0 nanogram per ml. were each added to 1 tube.
(4) Incubation took place for 20 hours at room temperature, the tubes being slowly rotated during the incubation period.
(5) 0.1 ml. of the solution containing I125 -growth hormone (approx. 2 nanogram per ml.) was each added to all tubes.
(6) Incubation as in item (4) but only for four hours.
(7) The particles were centrifuged down at 4000 revolutions per min. for 1 min.
(8) The particles were washed twice with a 0.9 percent aqueous solution of sodium chloride. After the last removal by suction of the supernatant the tubes were placed in counter tubes for estimating the gamma radiation from the antibody bound labeled hormone.
(9) The number of "counts" for a certain time for standard tubes were entered on a counts-dose diagram on a lin-log scale, from which the amount of growth hormone in the unknown test samples could then be calculated. (See separate FIG. 2).
Alternatively subsequent to the centriguing in item (7) 1 ml. of supernatant can be transferred into counter tubes, whereupon the gamma radiation from the free, labeled hormone can be estimated. "Counts" from these standard tubes can, in the same way, be entered into a count-dose diagram in lin-log scale and the amount of the growth hormone in the unknown test samples can then be estimated graphically from the connecting points in the same way as above.
EXAMPLE 3 Determination of Insulin in Blood Plasma.
(A) Preparation of antibodies: Guinea pigs were each injected subcutaneously with 0.5 mg. of pig insulin in 2 ml. of Freund's adjuvant. Immunization was repeated every week for four weeks. Subsequent to the passing of a further week, blood was drawn off from the guinea pigs and anti-serum recovered from the blood by allowing the same to coagulate, and removing the clots of blood.
The antibody fraction was precipitated from this anti-serum by treatment with a saturated aqueous solution of ammonium sulphate solution, 2.5 ml. of the latter being added to 5 ml. of serum.
The precipitate was separated by centriguation. The precipitate was dissolved in water and the precipitating process with ammonium sulphate solution was repeated twice. Subsequent to the third precipitating process the precipitate was dissolved in 0.1 ml. of an aqueous solution of sodium hydrogen carbonate, after which dialysis took place against 0.1 M sodium hydrogen carbonate solution. This antibody fraction was used for the coupling.
(B) Preparation of particles of covalent bound antibodies: This preparation took place in the same manner as under Example 1(B).
(C) Preparation of labeled insulin: Pig insulin was labeled with I125 according to the following method: 2 mc. I125 in the form of NaI was oxidized with Chloramine T in the presence of 5 μg. of insulin in accordance with a method described by Hunter and Greenwood (ref. Nature/London/, volume 194/1962/, page 495). Subsequent to the labeling, sodium dithionite was added to convert the remaining amount of iodine to soluble iodide. The obtained insulin labeled with I125 was mixed with bovine plasma-albumin and separated from low molecular weight products and from denaturation products of insulin bound to the plasma-albumin by gel filtration on a copolymer dextran with epichlorohydrin (Sephadex G-50). The insulin labeled in this way has a specific activity of 100-200 mc. per mg. The second peak of the labeled protein fraction was collected in a small vessel containing 1/2 ml. of a solution of bovine plasma-albumin containing 50 mg. per ml. The labeled hormone was stored in cold surroundings and diluted before being used.
(D) Determination: The analyses are suitably effected in glass or plastic tubes 50 × 10 mm.
(1) 1 ml. of a suspension of polymer particles (e.g. 1 mg./ml.) to which the antibodies have been bound was introduced into each of all tubes.
(2 ) 0.1 ml. of the plasma to be tested was added to one tube.
(3 ) 0.1 ml. of a standard solution having different concentration of the hormone, e.g. 200, 100, 50, 25, 10, 5 and 2.5 μE/ml. and 0 μE/ml. were each added to 1 tube.
(4 ) 0.1 of a solution containing I125 -insulin (approx. 1 nanogram per ml.) was added to all tubes.
(5 ) Incubation took place for 20 hours at room temperature or +4° C., the tubes being slowly rotated during the incubation period.
(6) The particles were centifuged down at 4000 revolutions per min. for 1 minute.
(7) The particles were washed twice with a 0.9 percent aqueous solution of sodium chloride. After the last removal by suction of the supernatant the tubes were placed in counter tubes for estimating the gamma radiation from the antibody bound labeled hormone.
(8) The number of "counts" for a certain time for standard tubes were entered on a counts-dose diagram on a lin-log scale, from which the amount of insulin in the unknown test samples could then be calculated. See separate FIG. 3.
Alternatively subsequent to the centrifuging in item (7) 1 ml. of supernatant can be transferred into counter tubes, whereupon the gamma radiation from the free, labeled hormone can be estimated. "Counts" from these standard tubes can, in the same way, be entered into a count-dose diagram in lin-log scale and the amount of insulin in the unknown test samples can then be estimated graphically from the connecting points in the same way as above.

Claims (4)

What is claimed is:
1. A method for the determination of a member selected from the group consisting of proteins and polypeptides in aqueous samples, which comprises contacting particles of water insoluble polymers to which have been bound, by covalent bonds, antibodies against the said member to be determined, with the aqueous sample containing said member and with the same member labelled with a radioactive isotope to bind part of said labelled member and unlabelled member to said antibodies to produce a two-phase system comprising a solid phase comprising said bound part of labelled member and unlabelled member and a liquid phase comprising unbound labelled member and unlabelled member, separating the two phases from each other, and measuring the radioactivity of at least one of the said solid and said liquid phases, the value of said radioactivity being each a function of the concentration of the said member in the aqueous sample.
2. A method as claimed in claim 1, wherein the solid phase is washed with an aqueous liquid before measuring the radioactivity of said phase.
3. A method as claimed 1, wherein the determination is effected quantitatively by comparing the measured value of the radioactivity with a standard curve. .Iadd. 4. A method as claimed in claim 3, wherein said antibodies have been covalently bound to said particles under conditions sufficiently mild to ensure that the reactivity of said antibodies does not substantially decrease. .Iaddend..Iadd. 5. A method as claimed in claim 4, wherein said covalent bonds are formed through a group of the formula --NH·CS·NH--, --NH·CO·NH--, or --N=N--. .Iaddend..Iadd. 6. A method as claimed in claim 5, wherein said group is --NH·CS·NH--. .Iaddend..Iadd. 7. A method as claimed in claim 3, wherein said water-insoluble polymers contain at least one reactive group selected from the group consisting of amino, hydroxyl and carboxyl. .Iaddend..Iadd. 8. A method as claimed in claim 7, wherein said reactive group is hydroxyl. .Iaddend..Iadd. 9. A method as claimed in claim 7, wherein said reactive group is amino. .Iaddend..Iadd. 10. A method as claimed in claim 3, wherein said polymer is obtained by crosslinking a material selected from the group consisting of carbohydrates, sugar alcohols, and polyvinyl alcohol, with a bifuctional compound of the formula X--R--Z, wherein X and Z are each independently halogen or epoxy, and R is an aliphatic radical containing from 3 to 10 carbon atoms. .Iaddend..Iadd. 11. A method as claimed in claim 10, wherein said material is dextran and said bifunctional compound is epichlorohydrin. .Iaddend..Iadd. 12. A method as claimed in claim 3,
wherein said member is a plasma protein. .Iaddend..Iadd. 13. A method as claimed in claim 3, wherein said member is an enzyme. .Iaddend..Iadd. 14. A method as claimed in claim 3, wherein said member is a hormone. .Iaddend..Iadd. 15. A method as claimed in claim 3, wherein said member is insulin. .Iaddend..Iadd. 16. A method as claimed in claim 3, wherein said member is a gonadotropin. .Iaddend..Iadd. 17. A method as claimed in claim 3, wherein said member is growth hormone. .Iaddend..Iadd. 18. A method as claimed in claim 3, wherein said member is ACTH. .Iaddend..Iadd. 19. A method as claimed in claim 3, wherein said member is thyrotropin. .Iaddend..Iadd. 20. A method as claimed in claim 3, wherein said member is parathormone. .Iaddend..Iadd. 21. A method as claimed in claim 3, wherein said aqueous sample is from blood serum. .Iaddend..Iadd. 22. A method as claimed in claim 3, wherein said aqueous sample is from urine. .Iaddend..Iadd. 23. A method as claimed in claim 3, wherein said radioactive isotope is I125, I131, C14, or H3..Iaddend.
US05/598,141 1966-06-02 1975-07-23 Method for the determination of proteins and polypeptides Expired - Lifetime USRE29474E (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US05/598,141 USRE29474E (en) 1966-06-02 1975-07-23 Method for the determination of proteins and polypeptides

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE7541/66A SE343949B (en) 1966-06-02 1966-06-02
SW7541/66 1966-06-02
US64319067A 1967-06-02 1967-06-02
US05/598,141 USRE29474E (en) 1966-06-02 1975-07-23 Method for the determination of proteins and polypeptides

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US64319067A Reissue 1966-06-02 1967-06-02

Publications (1)

Publication Number Publication Date
USRE29474E true USRE29474E (en) 1977-11-15

Family

ID=27354438

Family Applications (1)

Application Number Title Priority Date Filing Date
US05/598,141 Expired - Lifetime USRE29474E (en) 1966-06-02 1975-07-23 Method for the determination of proteins and polypeptides

Country Status (1)

Country Link
US (1) USRE29474E (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217338A (en) 1975-11-13 1980-08-12 Institut National De La Sante Et De La Recherche Medicale - Inserm Novel supports carrying side chains, processes for obtaining these supports, process for attaching organic compounds having carbohydrate residues on said supports, products and reagents resulting from said _chemical fixation
US4293310A (en) 1980-03-14 1981-10-06 University Of Pittsburgh Photoelectrochemical immunoassay
US4332783A (en) 1978-08-17 1982-06-01 Behringwerke Aktiengesellschaft Process for immunologic determination tests
US4394391A (en) 1980-02-19 1983-07-19 Thorell Jan Ivan Radioimmunoassay reagents
US4397960A (en) 1978-01-26 1983-08-09 Technicon Instruments Corporation Immunoassays using F(AB')2 fragments
US4459361A (en) 1982-06-04 1984-07-10 Angenics, Inc. Ligand assay with one or two particulate reagents and filter
EP0123403A3 (en) * 1983-03-15 1986-02-05 Boots-Celltech Diagnostics Limited Heterogeneous binding assay
US4652533A (en) 1983-04-28 1987-03-24 Pandex Laboratories, Inc. Method of solid phase immunoassay incorporating a luminescent label
EP0222146A3 (en) * 1985-10-16 1987-10-07 Humboldt-Universitat Zu Berlin Selective adsorbent for binding immunocouplers
US4920061A (en) 1984-03-02 1990-04-24 The University Of Texas System Biological magnetic colloids
US5141848A (en) * 1987-01-21 1992-08-25 Abbott Laboratories Confirmatory immunoassay using microparticle separation
US5429929A (en) * 1991-04-19 1995-07-04 The Trustees Of Columbia University In The City Of New York Method for detecting antibodies to a neuroblastoma antigen in mental illness

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2770602A (en) * 1951-06-25 1956-11-13 Aloe Company As Method of preparing protein standardized reagents
US2911338A (en) * 1954-03-09 1959-11-03 Abbott Lab Capsules and method of producing
GB938828A (en) * 1960-10-04 1963-10-09 Abbott Lab Improvements in or relating to pharmaceutical capsules comprising radioactive materials

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2770602A (en) * 1951-06-25 1956-11-13 Aloe Company As Method of preparing protein standardized reagents
US2911338A (en) * 1954-03-09 1959-11-03 Abbott Lab Capsules and method of producing
GB938828A (en) * 1960-10-04 1963-10-09 Abbott Lab Improvements in or relating to pharmaceutical capsules comprising radioactive materials

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Bennington, Radioautographic Analysis of Soluble Antibody-Antigen Complexes, Chem. Abstracts, vol. 54, p. 17521A. *
Drizlikh et al., Biokhimiya, vol. 29, No. 6, pp. 1054 to 1062 (1964). *
Jagendorf et al., Biochem. Biophys. Acta, vol. 78, pp. 516 to 528 (1963). *
Munoz, John J., Some Newer Immunological Techniques, Analytical Chemistry, vol. 31, No. 6, pp. 981-985, June 1959. *
Pressman et al., Computer Programs for Paired and Triad Radioiodine Label Techniques, Chem. Abstracts, vol. 64, p. 5606G, 1966. *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217338A (en) 1975-11-13 1980-08-12 Institut National De La Sante Et De La Recherche Medicale - Inserm Novel supports carrying side chains, processes for obtaining these supports, process for attaching organic compounds having carbohydrate residues on said supports, products and reagents resulting from said _chemical fixation
US4397960A (en) 1978-01-26 1983-08-09 Technicon Instruments Corporation Immunoassays using F(AB')2 fragments
US4332783A (en) 1978-08-17 1982-06-01 Behringwerke Aktiengesellschaft Process for immunologic determination tests
US4394391A (en) 1980-02-19 1983-07-19 Thorell Jan Ivan Radioimmunoassay reagents
US4293310A (en) 1980-03-14 1981-10-06 University Of Pittsburgh Photoelectrochemical immunoassay
US4459361A (en) 1982-06-04 1984-07-10 Angenics, Inc. Ligand assay with one or two particulate reagents and filter
EP0123403A3 (en) * 1983-03-15 1986-02-05 Boots-Celltech Diagnostics Limited Heterogeneous binding assay
US4656143A (en) 1983-03-15 1987-04-07 Baker Terence S Heterogeneous binding assay
US4652533A (en) 1983-04-28 1987-03-24 Pandex Laboratories, Inc. Method of solid phase immunoassay incorporating a luminescent label
US4920061A (en) 1984-03-02 1990-04-24 The University Of Texas System Biological magnetic colloids
EP0222146A3 (en) * 1985-10-16 1987-10-07 Humboldt-Universitat Zu Berlin Selective adsorbent for binding immunocouplers
US5141848A (en) * 1987-01-21 1992-08-25 Abbott Laboratories Confirmatory immunoassay using microparticle separation
US5429929A (en) * 1991-04-19 1995-07-04 The Trustees Of Columbia University In The City Of New York Method for detecting antibodies to a neuroblastoma antigen in mental illness

Similar Documents

Publication Publication Date Title
US3555143A (en) Method for the determination of proteins and polypeptides
US4048298A (en) Solid phase double-antibody radioimmunoassay procedure
US3646346A (en) Antibody-coated tube system for radioimmunoassay
Dawes et al. The release, distribution, and clearance of human β-thromboglobulin and platelet factor 4
US4108974A (en) Radioimmunoassay for thyroid hormone
US4353982A (en) Immunochemical assay for creatine kinase-MB isoenzyme
US3714345A (en) Stabilized erythrocyees and methods therefore
US4146603A (en) Tumor specific glycoproteins and method for detecting tumorigenic cancers
USRE29474E (en) Method for the determination of proteins and polypeptides
EP0064274B1 (en) Method for assaying antigen-antibody reactions and reagent therefor
CH631015A5 (en) METHOD FOR PRODUCING A REAGENT FOR DETECTING OR DETERMINING ANTIBODIES, ANTIGENS AND ANTIBODIES / ANTIGENS COMPLEXES IN A LIQUID.
EP0013930B1 (en) Immunogene, antibody for a thymus hormone, labelled thymus hormone and process for the determination of this thymus hormone
EP0267951A1 (en) Specific immunoassay for heparin
EP0001223A2 (en) Latex coated with a polyhydroxy compound, process for the preparation of this latex, immunological reagent containing this latex, process for the preparation of this reagent, application of this reagent, testing procedure utilising this reagent and reagent kit containing this reagent
US3992517A (en) Detection of hepatitis B surface antigen by latex agglutination
US3956258A (en) Carcinoembryonic antigens
US3689633A (en) Preparation of test sample for immunological assay of pregnancy of mares
US3896218A (en) Radiommunoassay determining the hepatitis associated antigen content of blood
US3505019A (en) Method for determining vitamin b12 and reagent therefor
NO127685B (en)
Brunfeldt et al. The antigenic properties of pig insulin
US3840655A (en) Diagnostic methods and reagents for infectous mononucleosis
USRE29480E (en) Method for determining vitamin B12 and reagent therefor
Ryan et al. Methods for establishing a working immunoradiometric assay for serum ferritin
Wang et al. Semi-automatic solid-phase radioimmunoassay for carcinoembryonic antigen